NCT02402920 2026-03-10
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
44 trialsNCT03211988 2026-03-02
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Phase 2 Terminated
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT03289741 2025-05-09
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT06456723 2025-05-01
FETONET
Imperial College London
Phase 1/2 Completed
NCT04986085 2025-03-28
NUTRIGETNE
Grupo Espanol de Tumores Neuroendocrinos
Completed
NCT05680675 2025-02-06
Dual-Tracer Theranostic PET
University of Utah
Phase NA Completed
NCT03980925 2025-01-13
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT03095274 2025-01-09
DUNE
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT03034200 2024-11-26
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01678664 2024-09-25
EVACEL
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03420521 2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02859064 2023-12-05
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT03136328 2023-05-09
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Montefiore Medical Center
Phase 3 Completed
NCT01253161 2023-03-06
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03273712 2023-02-09
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
Phase 2 Completed
NCT02609737 2022-02-01
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01218555 2022-01-27
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
Phase 1 Completed
NCT01869725 2021-09-22
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Phase 2 Completed
NCT03190213 2021-06-22
Pembro NEC
University of Utah
Phase 2 Terminated
NCT03670030 2021-06-10
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Ochsner Health System
Phase 2 Terminated
NCT02441062 2020-12-21
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa
Phase 2 Completed
NCT00171873 2020-03-26
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Philipps University Marburg
Phase 3 Completed
NCT00985946 2019-12-09
Study of Panobinostat in Patients With Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 2 Terminated
NCT00501540 2019-11-26
Lithium for Low-Grade Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 2 Completed
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT01280201 2019-05-29
Pazopanib as Single Agent in Advanced NETs
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01290536 2019-03-01
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
University of California, San Francisco
Phase 2 Completed
NCT00605566 2019-02-19
Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors
University Health Network, Toronto
Phase 2 Completed
NCT01024387 2018-03-08
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01177007 2017-08-28
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
Phase 2 Completed
NCT01719861 2017-04-17
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT00398320 2017-03-01
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT01396382 2016-03-29
68Ga
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT01169649 2016-02-18
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00610129 2015-11-20
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01886287 2015-01-12
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00434109 2012-09-14
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed